According to a preclinical study conducted by Weill Cornell Medicine researchers, it may soon be feasible to detect whether individuals with hepatocellular carcinoma, a kind of liver cancer, may benefit from immunotherapy.
In theory, a team from the University of Massachusetts Amherst proved that a protein antigen from a childhood vaccine may be administered into the cells of a malignant tumour to reorient the body's immune system against the cancer, effectively stopping it and preventing its recurrence.
Researchers discovered that cancer frequently sends substances into the bloodstream that pathologically alter the liver, putting it in an inflammatory condition, causing fat to build up, and interfering with its regular detoxification functions.
Researchers at Weill Cornell Medicine found that cancer often releases molecules into the bloodstream that pathologically modify the liver, sending it into an inflammatory state, causing fat accumulation, and disrupting its typical detoxification processes. This finding sheds light on one of
Hepatocellular carcinoma (HCC), the most common type of liver cancer, is already the third leading cause of cancer-related deaths worldwide--and cases are on the rise in both the United States and around the world. While chemotherapy, surgery, and liver transplants can benefit some patients,
Heidelberg [Germany], August 19 (ANI): The cell of origin of mixed liver/biliary duct carcinomas, a rare type of liver cancer, has been found in mice by researchers from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the Hebrew University in Jerusalem. Carcino